ChinaBio Today Release: Barclays Remains Negative on Most China Pharma Stocks Near-Term

April 4, 2012 -- Based in part on a ChinaBio® survey, Barclays has reiterated its downbeat outlook for China healthcare companies for the rest of 2012. The ChinaBio study showed that industry participants remain pessimistic about the near-term future. Jason Mann, MD, PhD, the Barclays analyst for the sector, used the survey results to underline the difference between insiders, who see more difficulties ahead, and outsiders, who remain overly optimistic in his opinion. More details....